NCT02908451 is a Phase 1 clinical trial of AbGn-107 in Gastric Cancer, sponsored by AbGenomics B.V Taiwan Branch.

Who is sponsoring NCT02908451?

NCT02908451 is sponsored by AbGenomics B.V Taiwan Branch.

What drugs are being tested in NCT02908451?

Interventions in NCT02908451: AbGn-107.

What condition does NCT02908451 study?

NCT02908451 studies Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Biliary Cancer.

Is NCT02908451 still recruiting?

NCT02908451 is currently terminated. Last updated 13 July 2021.

Last reviewed 2021-07-13 · How we verify

NCT02908451

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer

Terminated Phase 1 Last updated 13 July 2021

What this trial tests

Phase 1 trial testing AbGn-107 in Gastric Cancer in 39 participants. Terminated before completion.

Timeline

24 April 2017

Primary endpoint
28 February 2021

28 February 2021

Quick facts

Lead sponsor	AbGenomics B.V Taiwan Branch
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	39
Start date	24 April 2017
Primary completion	28 February 2021
Estimated completion	28 February 2021
Sites	9 locations across Taiwan, United States

Drugs / interventions tested

AbGn-107 — full drug profile →

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →
Colorectal Cancer — all drugs for Colorectal Cancer →
Pancreatic Cancer — all drugs for Pancreatic Cancer →
Biliary Cancer — all drugs for Biliary Cancer →

Sponsor

AbGenomics B.V Taiwan Branch — full company profile →

Who can join

18 and older, any sex, with Gastric Cancer or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 14 days (Q2W regimen) or 28 days (Q4W regimen) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal, pancreatic or biliary cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U, Parakh S, Gan HK, Scott AM. · · 2020 · cited 283× · PMID 33081383 · DOI 10.3390/molecules25204764
Targeting cancer with antibody-drug conjugates: Promises and challenges.
Dean AQ, Luo S, Twomey JD, Zhang B. · · 2021 · cited 145× · PMID 34291723 · DOI 10.1080/19420862.2021.1951427
Current and novel therapeutic opportunities for systemic therapy in biliary cancer.
Marin JJG, Prete MG, Lamarca A, Tavolari S, et al · · 2020 · cited 45× · PMID 32694694 · DOI 10.1038/s41416-020-0987-3
Antibody drug conjugates: hitting the mark in pancreatic cancer?
Wittwer NL, Brown MP, Liapis V, Staudacher AH. · · 2023 · cited 22× · PMID 37880707 · DOI 10.1186/s13046-023-02868-x
Systemic treatment options for advanced biliary tract carcinoma.
Xie C, McGrath NA, Monge Bonilla C, Fu J. · · 2020 · cited 17× · PMID 32748173 · DOI 10.1007/s00535-020-01712-9
Unraveling the glyco-immunity nexus in pancreatic cancer.
Rajesh C, Cummings RD, Radhakrishnan P. · · 2025 · cited 2× · PMID 40759948 · DOI 10.1186/s12943-025-02417-4
A multicenter phase Ia study of AbGn-107, a novel antibody-drug conjugate, in patients with advanced gastrointestinal cancer.
Ko AH, Coveler AL, Schlechter BL, Bekaii-Saab T, et al · · 2024 · cited 1× · PMID 38441850 · DOI 10.1007/s10637-024-01430-6
Targeted Therapy in Hepatobiliary Pancreatic Cancer (HPC): Advantages and Advancements of Antibody Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs.
Deb Nath T, Mukherjee A, Chauhan SC, Bandyopadhyay D. · · 2026 · PMID 41898574 · DOI 10.3390/ijms27062707

Verify or expand the search:

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02908451 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AbGenomics B.V Taiwan Branch
Last refreshed: 13 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02908451.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing